Deep research
About Larazotide Acetate
Larazotide acetate (also known as AT-1001) is a synthetic octapeptide with a molecular weight of approximately 1024 Da, derived from an active fragment of the zonula occludens toxin (Zot) produced by Vibrio cholerae. The peptide was developed by Dr. Alessio Fasano and colleagues at the University of Maryland Center for Celiac Research based on the discovery that Zot regulates intestinal permeability through the same pathway as the endogenous human protein zonulin. While Zot opens tight junctions (which is how cholera causes secretory diarrhea), larazotide was engineered to act as a competitive antagonist at the zonulin receptor, blocking tight junction disassembly rather than promoting it.
The mechanism of action centers on the zonulin pathway. Zonulin (pre-haptoglobin 2) is the only known physiological modulator of intercellular tight junctions in the human intestine. When zonulin binds to its receptor on the basolateral surface of enterocytes, it activates a signaling cascade involving phospholipase C, protein kinase C-alpha, and polymerization of intracellular actin filaments. This cytoskeletal rearrangement physically pulls apart the tight junction proteins (claudins, occludin, ZO-1, ZO-2) that seal the paracellular space between epithelial cells. The result is increased intestinal permeability, allowing luminal contents, including incompletely digested food proteins (such as gliadin fragments), bacterial lipopolysaccharides (LPS), and other antigens, to cross into the lamina propria where they activate the mucosal immune system. Larazotide competitively blocks zonulin receptor binding, preventing this entire cascade and keeping the tight junction complex intact.
The clinical evidence for larazotide comes from a rigorous trial program. The Phase 2b trial (Leffler et al., 2015, published in Gastroenterology, DOI: 10.1053/j.gastro.2015.02.008) enrolled 342 celiac disease patients on a gluten-free diet and randomized them to larazotide acetate (0.5 mg, 1 mg, or 2 mg three times daily) or placebo for 12 weeks. The 0.5 mg dose produced a statistically significant 26% reduction in celiac symptom scores (CeD-PRO) compared to placebo (p=0.022), with particular improvement in abdominal pain, bloating, and diarrhea. Interestingly, the 0.5 mg dose was more effective than the higher doses, consistent with a local luminal mechanism where lower concentrations optimally saturate the zonulin receptor in the proximal small intestine. A Phase 3 trial has been conducted to confirm these findings in a larger population.
Larazotide is relevant far beyond celiac disease. Elevated zonulin levels and increased intestinal permeability have been documented in type 1 diabetes, inflammatory bowel disease (both Crohn's and ulcerative colitis), irritable bowel syndrome, non-alcoholic fatty liver disease (NAFLD), rheumatoid arthritis, multiple sclerosis, and ankylosing spondylitis. The concept of pathological intestinal permeability, sometimes called 'leaky gut,' was once dismissed but is now supported by hundreds of peer-reviewed publications and recognized as a contributing factor in autoimmune and inflammatory conditions. By sealing tight junctions, larazotide addresses a root mechanism shared across these conditions rather than merely suppressing downstream symptoms.
The pharmacokinetic profile of larazotide is notable for its local action. The peptide acts in the intestinal lumen and has minimal systemic absorption, which is actually desirable for its mechanism. Because it works at the epithelial surface rather than requiring systemic distribution, it achieves therapeutic concentrations at the site of action while producing negligible plasma levels. This local mechanism is confirmed by the absence of systemic side effects in clinical trials and by transepithelial electrical resistance (TEER) assays showing that larazotide prevents zonulin-induced TEER decreases in intestinal epithelial monolayers.
As an oral capsule, larazotide requires no reconstitution or injection. Store at room temperature (20-25 degrees C) in the original packaging. No refrigeration is required. The capsule formulation is designed to release the peptide in the proximal small intestine (duodenum and jejunum), which is where zonulin-mediated permeability changes are most pronounced in celiac disease and where gluten-induced damage primarily occurs.
The safety profile of larazotide is exceptionally clean. In the Phase 2b trial with 342 patients over 12 weeks, the adverse event rate in the larazotide groups was statistically indistinguishable from placebo. The most commonly reported events (headache, upper respiratory tract infection, urinary tract infection) occurred at equal or lower rates than in the placebo group. No serious adverse events were attributed to larazotide. This is consistent with the local, non-systemic mechanism: because the peptide does not enter the bloodstream in meaningful quantities, it does not produce off-target systemic effects. Larazotide has been studied at doses up to 8 mg three times daily without dose-limiting toxicities.
